



OMOP CDM Oncology Module at Work

Rimma Belenkaya, Michael Gurley, Christian Reich, Dmitry Dymshyts, Jeremy Warner, Robert Miller, Andrew Williams, RuiJun Chen



OHDSI Oncology WG



Northwestern University









Tufts Clinical and Translational Science Institute























Challenges: Granularity


Normal Condition

Most normal conditions are defined by three main dimensions implicitly, plus some extra attributes



Cancer


- •Cause is not known, but morphology and topology are detailed and explicit
- •The many tumor attributes (modifiers) are also explicit and well defined





Challenges: Abstraction


• Clinically and analytically relevant representation of cancer diagnoses, treatments, and outcomes requires data abstraction



- Not readily available in the source data
- Traditionally not supported in OMOP CDM




Solving Granularity Challenge





Solving Granularity Challenge

Cancer diagnosis representation in the OMOP CDM




- Precoordinated concept of cancer
 Morphology + Site is stored in
 Condition_Occurrence
- Diagnostic modifiers are stored in Measurement and linked to the Condition_Occurrence record



Solving Granularity Challenge

Cancer diagnosis representation in the OMOP CDM



Example of cancer diagnosis in the OMOP CDM

Histology+Site diagnosis in Condition_Occurrence

- Precoordinated concept of cancer
 Morphology + Site is stored in
 Condition_Occurrence
- Diagnostic modifiers are stored in Measurement and linked to the Condition_Occurrence record


	condition_occurrence_id	123456789	
	person_id	1	
	condition_concept_id	4116071	← SNOMED concept 'Carcinoma of breast'
	condition_start_datetime	June 9, 2019	
	condition_type_concept_id	32535	
	condition_source_value	8010/3-C50.9	◆ Precoordinated concept of ICD-O Histology & Site
	condition_source_concept_id	44505310	

Grade modifier in **Measurement**

measurement_id	567890	
person_id	1	
measurement_datetime	June 9, 2019	
measurement_concept_id	35918640	◆ NAACCR concept 'Grade Pathological'
measurement_date	June 9, 2019	
value_as_concept_id	35922509	◆ NAACCR concept 'G3: High combined histologic grade (unfavorable); SBR score of 8-9 points'
measurement_type_concept_id	32534	◆ OMOP concept 'Tumor registry'
measurement_source_value	3844	◆ NAACCR code for 'Grade Pathological'
measurement_source_concept_id	35918640	◆ NAACCR concept 'Grade Pathological'
value_source_value	breast@3844@3	NAACCR code for 'G3: High combined histologic grade (unfavorable); SBR score of 8-9 points'
modifier_of_event_id	123456789	◆ Value of the respective condition record condition_occurrence_id
modifier field concept id	1147127	Concept for 'condition_occurrence.condition_occurrence_id'




Solving Abstraction Challenge





Solving Abstraction Challenge






Testing


- Developed vocabulary-driven ETL for data conversion from Tumor Registry
- Converted EHR and Tumor Registry data from four participating institutions
- Tested clinical characterization use cases
 - Survival from initial diagnosis
 - Time from diagnosis to treatment
 - High-level treatment course for 1st cancer occurrence
 - Derivation of chemotherapy regimens from atomic drugs




Survival from diagnosis


Metastatic vs. Non-metastatic cancers





Six most prevalent cancers







Join the Effort!

- CDM and Vocabulary Work
 - Adding domains for genomics, imaging and outcomes
 - Improving ICD-O-3 to SNOMED mapping precision
 - Mapping of NAACCR data dictionary to SNOMED
- Oncology-specific THEMIS conventions
- ETL
 - Validation
 - Conventions and algorithms for fusing tumor registry and EHR data on the same patient
- Use-case-driven algorithms for
 - identifying & characterizing cancer populations
 - identifying treatment pathways and disease progression
 - predicting disease progression

<u>belenkar@mskcc.org</u> <u>m-gurley@northwestern.edu</u>



Many thanks to

Charles Bailey, Children's Hospital of Philadelphia, US Scott Campbell, University of Nebraska, US Rachel Chee, IQVIA, Great Britain Mark Danese, Outcome Insights, US Asieh Golozar, Regeneron, US George Hripcsak, Columbia University, US Ben May, Columbia University, US **Maxim Moinat**, The Hyve, Netherlands Anna Ostropolets, Columbia University, US Meera Patel, MSK, US Joseph Plasek, Aurora, US **Gurvaneet Randhawa**, NCI, US Donna Rivera, NIH, US Mitra Rocca, FDA, US **Anastasios Siapos**, IQVIA, Great Britain Firas Wehbe, Northwestern University, US **Seng Chan You**, Ajou University School of Medicine, Korea



Thank you!



Thank you!